Pyridoxamine

Pyridoxamine

SCHEMBL48103

Cc1ncc(CO)c(CN)c1O.Cl.Cl

nearest known ligand 0.96

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO

The experimentally established mechanism targets of Pyridoxamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA known ✓ P10253 1/20 0.46
CA2 known ✓ P00918 3/20 0.45
DPP4 known ✓ P27487 1/20 0.39
HDAC1 known ✓ Q13547 1/20 0.39
LMNA P02545 2/20 0.96
KDM4E B2RXH2 3/20 0.73
ALDH1A1 P00352 2/20 0.73
HPGD P15428 2/20 0.73
HSD17B10 Q99714 1/20 0.73
TRIM24 O15164 1/20 0.54
TRIM33 Q9UPN9 1/20 0.54
PDXK O00764 3/20 0.51
KMT2A Q03164 2/20 0.51
MEN1 O00255 1/20 0.51
AOX1 Q06278 1/20 0.51
CYP1A2 P05177 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
HIF1A Q16665 1/20 0.47
CA1 P00915 3/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pyridoxamine SCHEMBL561421 1.00 LMNA (0.96) LMNAKDM4EALDH1A1HPGDHSD17B10
Pyridoxamine SCHEMBL3555546 0.98 LMNA (0.93) LMNAKDM4EALDH1A1HPGDHSD17B10
Pyridoxamine SCHEMBL30408 0.98 LMNA (1.00) LMNAKDM4EALDH1A1HPGDHSD17B10
Pyridoxamine SCHEMBL7749395 0.96 LMNA (0.96) LMNAKDM4EALDH1A1HPGDHSD17B10
Pyridoxamine SCHEMBL9291549 0.95 LMNA (0.93) LMNAKDM4EALDH1A1HPGDHSD17B10
Pyridoxamine SCHEMBL4876978 0.95 LMNA (0.93) LMNAKDM4EALDH1A1HPGDHSD17B10
Pyridoxamine SCHEMBL11424618 0.93 LMNA (0.90) LMNAKDM4EALDH1A1HPGDHSD17B10
Pyridoxamine SCHEMBL43833 0.90 LMNA (0.84) LMNAKDM4EALDH1A1HPGDHSD17B10
Pyridoxamine SCHEMBL8904115 0.89 LMNA (0.82) LMNAKDM4EALDH1A1HPGDHSD17B10
Pyridoxamine SCHEMBL30017752 0.88 LMNA (0.79) LMNAKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 686 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122056386-A Moisture absorption resistant slow release microcapsule powder and preparation method and application thereof 大连医诺生物股份有限公司 2026-05-19 CN claimed
CN-122030612-A Shear-resistant slow-release microcapsule powder and preparation method and application thereof 大连医诺生物股份有限公司 2026-05-15 CN claimed
EP-3794005-B1 INORGANIC SALTS OF NICOTINIC ACID MONONUCLEOTIDE AS ANTI-AGING AGENTS Jumpstart Fertility Pty Ltd (AU) 2025-10-22 EP claimed
US-20250111893-A1 SYSTEMS AND METHODS FOR CUSTOMIZING CELL CULTURE MEDIA FOR OPTIMIZED CELL PROLIFERATION BASED ON GENETIC TRAITS OF CELLS WONDERLAB HOLDINGS, INC. 2025-04-03 US claimed
US-20250057865-A1 ANTIVIRAL SUPPLEMENT FORMULATIONS FOR HERPESVIRUS INFECTIONS Vymedic, Inc. 2025-02-20 US claimed
WO-2025038636-A1 ANTIVIRAL SUPPLEMENT FORMULATIONS FOR HERPESVIRUS INFECTIONS Vymedic, Inc. (US) 2025-02-20 WO claimed
CN-113498416-B Inorganic salts of nicotinic acid mononucleotide as anti-aging agents 江普斯塔特生育有限公司 2024-12-06 CN claimed
US-12087399-B2 Systems and methods for customizing cell culture media for optimized cell proliferation based on genetic traits of cells SAPPHIROS AI BIO LLC (US) 2024-09-10 US claimed
CN-114410505-B Clostridium thermocellum and its application in lignocellulose hydrolysis 苏州聚维元创生物科技有限公司 2023-10-24 CN claimed
CN-114058533-B Screening method of sulfate reducing bacteria capable of degrading polycyclic aromatic hydrocarbon 清华大学 2023-10-03 CN claimed
US-6746678-B1 Method of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with medicaments SECANT PHARMA, LLC 2004-06-08 US claimed
US-6444221-B1 ADMINISTERING AMINOBENZOIC ACID SECANT PHARMA, LLC 2002-09-03 US claimed
EP-0673434-B1 DEVICE FOR CARRYING OUT UREASE TESTS FOR COMBINED ANTRUM/CORPUS BIOPSIES TO DIAGNOSE GASTRO-INTESTINAL ILLNESSES ASTRA AB (SE) 1999-07-28 EP claimed
EP-0759750-A4 COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES SHAPIRO HOWARD K (US) 1998-05-27 EP claimed
US-5679570-A Device for performing urease tests on combined antrum/corpus biopsies to diagnose gastrointestinal illnesses HECKENMULLER HARALD (DE) 1997-10-21 US claimed
EP-0759750-A1 COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES SHAPIRO, Howard, K. (US) 1997-03-05 EP claimed
WO-1995031194-A1 COMPOSITIONS FOR TREATMENT OF CHRONIC INFLAMMATORY DISEASES SHAPIRO HOWARD K (US) 1995-11-23 WO claimed
EP-0673434-A1 DEVICE FOR CARRYING OUT UREASE TESTS FOR COMBINED ANTRUM/CORPUS BIOPSIES TO DIAGNOSE GASTRO-INTESTINAL ILLNESSES Astra Aktiebolag (SE) 1995-09-27 EP claimed
WO-1994013830-A1 DEVICE FOR CARRYING OUT UREASE TESTS FOR COMBINED ANTRUM/CORPUS BIOPSIES TO DIAGNOSE GASTRO-INTESTINAL ILLNESSES ASTRA CHEMICALS GMBH (DE) 1994-06-23 WO claimed
US-4115576-A 5-HYDROXYMETHYLCYTOSINE, A B6 VITAMIN, NICOTINAMIDE OR NICOTINIC ACID PENN NATHAR W 1978-09-19 US claimed